|
1
|
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
|
Lancet Oncol
|
2010
|
3.76
|
|
2
|
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.
|
J Clin Oncol
|
2008
|
2.44
|
|
3
|
Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients.
|
Leuk Lymphoma
|
2014
|
2.40
|
|
4
|
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
|
Blood
|
2012
|
2.37
|
|
5
|
Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy.
|
J Clin Oncol
|
2010
|
2.20
|
|
6
|
Lymphoma: risk and response after solid organ transplant.
|
Oncology (Williston Park)
|
2010
|
2.09
|
|
7
|
Improving the quality of bone marrow assessment: Impact of operator techniques and use of a specimen preparation checklist.
|
Cancer
|
2013
|
1.98
|
|
8
|
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
|
Biol Blood Marrow Transplant
|
2008
|
1.69
|
|
9
|
High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database.
|
Leuk Lymphoma
|
2012
|
1.62
|
|
10
|
Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
|
Biol Blood Marrow Transplant
|
2011
|
1.62
|
|
11
|
NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes.
|
Blood
|
2005
|
1.59
|
|
12
|
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.
|
Blood
|
2011
|
1.55
|
|
13
|
Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
|
Leuk Lymphoma
|
2012
|
1.54
|
|
14
|
Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant.
|
Leuk Lymphoma
|
2012
|
1.45
|
|
15
|
Non-Hodgkin's lymphomas, version 1.2013.
|
J Natl Compr Canc Netw
|
2013
|
1.20
|
|
16
|
Non-Hodgkin's lymphomas, version 4.2014.
|
J Natl Compr Canc Netw
|
2014
|
1.17
|
|
17
|
Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.
|
Clin Lymphoma Myeloma
|
2009
|
1.10
|
|
18
|
Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders.
|
Br J Haematol
|
2008
|
1.09
|
|
19
|
Non-Hodgkin's lymphomas.
|
J Natl Compr Canc Netw
|
2011
|
1.06
|
|
20
|
Nodular lymphocyte predominant Hodgkin lymphoma.
|
Oncologist
|
2009
|
1.06
|
|
21
|
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
|
Cancer
|
2010
|
1.05
|
|
22
|
Non-Hodgkin's Lymphomas, version 3.2012.
|
J Natl Compr Canc Netw
|
2012
|
1.03
|
|
23
|
Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.
|
Br J Haematol
|
2012
|
1.00
|
|
24
|
Enzastaurin.
|
Expert Opin Investig Drugs
|
2008
|
1.00
|
|
25
|
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
|
Cancer
|
2011
|
0.97
|
|
26
|
Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma.
|
Am J Surg Pathol
|
2007
|
0.94
|
|
27
|
Non-Hodgkin's lymphomas, version 2.2014.
|
J Natl Compr Canc Netw
|
2014
|
0.94
|
|
28
|
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
|
Cancer
|
2014
|
0.91
|
|
29
|
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
|
Cancer
|
2013
|
0.90
|
|
30
|
Diffuse Large B-Cell Lymphoma Version 1.2016.
|
J Natl Compr Canc Netw
|
2016
|
0.89
|
|
31
|
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.
|
Cancer Cell
|
2016
|
0.87
|
|
32
|
Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma.
|
Haematologica
|
2012
|
0.83
|
|
33
|
Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.83
|
|
34
|
Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project.
|
Cancer
|
2014
|
0.82
|
|
35
|
Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.
|
Br J Haematol
|
2013
|
0.81
|
|
36
|
Primary mediastinal large B-cell lymphoma.
|
Clin Adv Hematol Oncol
|
2009
|
0.81
|
|
37
|
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
|
J Natl Compr Canc Netw
|
2015
|
0.81
|
|
38
|
Biology of double-hit B-cell lymphomas.
|
Curr Opin Hematol
|
2012
|
0.79
|
|
39
|
Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma.
|
J Clin Oncol
|
2011
|
0.79
|
|
40
|
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network.
|
Cancer
|
2014
|
0.78
|
|
41
|
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
|
Haematologica
|
2013
|
0.76
|
|
42
|
Large vessel vasculopathy in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
|
Leuk Lymphoma
|
2013
|
0.75
|